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 Participating consortia and investigators  
The data used in the current report were derived from published results from The Meta-Analyses 
of Glucose and Insulin-related traits Consortium (MAGIC)1 and from unpublished meta-analyses 
from the African American Glucose and Insulin genetic Epidemiology (AAGILE) consortium. Only 
non-diabetic individuals were included in the trans-ethnic meta-analysis that combined data from 
MAGIC and AAGILE consortium. All data on participants of European ancestry (EA) were 
obtained from MAGIC (n = 51,750) while all data on participants of African ancestry (AA) were 
obtained from the AAGILE Consortium (n = 20,209). Cohorts that contributed data to the MAGIC 
consortium and names of the steering committee members are listed on the consortium website: 
http://www.magicinvestigators.org/.   
The AAGILE consortium includes AA individuals from 16 cohorts. Key characteristics for 
each discovery and replication study sample are shown in Table S1. Investigators from AAGILE 
consortium are listed in the author list while those from the MAGIC consortium are shown below. 
 
  
 MAGIC investigator 1 
 
Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, Rybin D, Liu CT, Bielak 
LF, Prokopenko I, Amin N, Barnes D, Cadby G, Hottenga JJ, Ingelsson E, Jackson AU, Johnson 
T, Kanoni S, Ladenvall C, Lagou V, Lahti J, Lecoeur C, Liu Y, Martinez-Larrad MT, Montasser 
ME, Navarro P, Perry JR, Rasmussen-Torvik LJ, Salo P, Sattar N, Shungin D, Strawbridge RJ, 
Tanaka T, van Duijn CM, An P, de Andrade M, Andrews JS, Aspelund T, Atalay M, Aulchenko Y, 
Balkau B, Bandinelli S, Beckmann JS, Beilby JP, Bellis C, Bergman RN, Blangero J, Boban M, 
Boehnke M, Boerwinkle E, Bonnycastle LL, Boomsma DI, Borecki IB, Böttcher Y, Bouchard C, 
Brunner E, Budimir D, Campbell H, Carlson O, Chines PS, Clarke R, Collins FS, Corbatón-
Anchuelo A, Couper D, de Faire U, Dedoussis GV, Deloukas P, Dimitriou M, Egan JM, Eiriksdottir 
G, Erdos MR, Eriksson JG, Eury E, Ferrucci L, Ford I, Forouhi NG, Fox CS, Franzosi MG, Franks 
PW, Frayling TM, Froguel P, Galan P, de Geus E, Gigante B, Glazer NL, Goel A, Groop L, 
Gudnason V, Hallmans G, Hamsten A, Hansson O, Harris TB, Hayward C, Heath S, Hercberg S, 
Hicks AA, Hingorani A, Hofman A, Hui J, Hung J, Jarvelin MR, Jhun MA, Johnson PC, Jukema 
JW, Jula A, Kao WH, Kaprio J, Kardia SL, Keinanen-Kiukaanniemi S, Kivimaki M, Kolcic I, Kovacs 
P, Kumari M, Kuusisto J, Kyvik KO, Laakso M, Lakka T, Lannfelt L, Lathrop GM, Launer LJ, 
Leander K, Li G, Lind L, Lindstrom J, Lobbens S, Loos RJ, Luan J, Lyssenko V, Mägi R, 
Magnusson PK, Marmot M, Meneton P, Mohlke KL, Mooser V, Morken MA, Miljkovic I, Narisu N, 
O'Connell J, Ong KK, Oostra BA, Palmer LJ, Palotie A, Pankow JS, Peden JF, Pedersen NL, 
Pehlic M, Peltonen L, Penninx B, Pericic M, Perola M, Perusse L, Peyser PA, Polasek O, 
Pramstaller PP, Province MA, Räikkönen K, Rauramaa R, Rehnberg E, Rice K, Rotter JI, Rudan 
I, Ruokonen A, Saaristo T, Sabater-Lleal M, Salomaa V, Savage DB, Saxena R, Schwarz P, 
Seedorf U, Sennblad B, Serrano-Rios M, Shuldiner AR, Sijbrands EJ, Siscovick DS, Smit JH, 
Small KS, Smith NL, Smith AV, Stančáková A, Stirrups K, Stumvoll M, Sun YV, Swift AJ, Tönjes 
A, Tuomilehto J, Trompet S, Uitterlinden AG, Uusitupa M, Vikström M, Vitart V, Vohl MC, Voight 
BF, Vollenweider P, Waeber G, Waterworth DM, Watkins H, Wheeler E, Widen E, Wild SH, 
Willems SM, Willemsen G, Wilson JF, Witteman JC, Wright AF, Yaghootkar H, Zelenika D, 
Zemunik T, Zgaga L; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium; 
Multiple Tissue Human Expression Resource (MUTHER) Consortium, Wareham NJ, McCarthy 
MI, Barroso I, Watanabe RM, Florez JC, Dupuis J, Meigs JB, Langenberg C. 
 
  
 Sources of data for pleiotropy studies  
 
Consortia that contributed results for associations between fasting glucose or fasting insulin SNPs 
and insulin-related traits (i.e., hypertension, systolic and diastolic blood pressure, triglycerides, 
high density lipoprotein cholesterol, low density lipoprotein cholesterol, body mass index and 
waist-to-hip ratio-adjusted for BMI) are shown below: 
 
1. Continental Origins and Genetic Epidemiology Network (COGENT) consortium2 
The COGENT consortium provided association results for hypertension and for systolic 
and diastolic blood pressure. 
2. Electronic Medical Records and Genomics Network (eMERGE)3 
The eMERGE consortium provided triglyceride data from BioVU at Vanderbilt University 
Medical Center (https://victr.vanderbilt.edu/pub/biovu/) and triglyceride and blood 
pressure (hypertension and systolic and diastolic blood pressure) data from Mt. Sinai 
School of Medicine.  
3. The National, Heart, Lung and Blood Institute’s Candidate gene Association 
Resource (CARe)4 
The CARe consortium contributed association results for high density lipoprotein 
cholesterol and low density lipoprotein cholesterol. 
4. MEta-analysis of type 2 DIabetes in African Americans (MEDIA) Consortium5   
The MEDIA consortium provided association results for type 2 diabetes. 
5. African Ancestry Anthropometry Genetics (AAAG) Consortium6,7  
The AAAG consortium provided association results for body mass index and waist-hip-
ratios. 
  
 Author contributions 
The contributions of authors are summarized below: 
Assembling and steering the consortium: AA, APM, BMP, CNR, CTL, DJC, DKA, DS, DWB, EB, 
EPB, IM, JBM, JCF, JD, JGW, JIR, JSP, LEW, LF, MAN, MAP, MMS, RJFL, SSR, YIC 
 
Genotyping and data imputation: AA, EPB, GC, JAS, JIR, JY, KDT, LJRT, MAP, MF, MMS, MOG, 
RJFL, SLRK, TT, XG, YIC, YL 
 
Phenotyping of the study participants: ANK, DS, EPB, JAP, JIR, JK, JMZ, MAP, MLB, PAP, RJFL, 
RK, SLRK, YIC, YL 
 
Statistical analyses: AA, ABZ, AC, ADJ, AHZ, AJK, ALP, AMD, ARB, BEC, BP, CA, CDL, CTL, 
DC, DV, DS, DSE, DVR, DWB, EKK, EPB, ES, GC, JACD, JD, JDE, JH, JL, JL, JTZ, JY, KEN, 
KJG, KMR, LAL, LFB, LL, LLA, LRY, MAJ, MAP, MBS, MC, MCYN, MFK, MGH, MKE, ML, MPW, 
MRI, MS, NA, NF, NM, OG, PA, PAP, RAJ, RK, SL, SR, SRP, SS, ST, TBH, THM, TLE, TT, UN, 
WLL, WMC, WMC, WZ, XG, XL, XZ, YL, YL, YPF 
 
SNP annotation: AMD, KJG, LL, JH, SR, KH 
 
Drafting of the manuscript: AMD, APM, ASL, CTL, DS, DMB, DV, EKK, EPB, ES, JBM, JCF, JD, 
JGW, JH, JIR, KDT, KH, KJG, LL, LRY, MCYN, MD, MFH, MGH, ML, MOG, MMS, NM, PA, RJFL, 
RK, SR, SSR, WHLK, WMC, XG, XL, YIC, YL 
 
Enhancing the manuscript for intellectual content: All authors 
Approval of the final version: All authors 
 
 
  
 SNP annotation  
Following trans-ethnic meta-analysis of data from MAGIC (EA participants) and the AAGILE 
consortium (AA participants), we identified 14 fasting glucose (FG) and 9 fasting insulin (FI) loci 
(Table S5) in which the number of SNPs in a locus or the size of the genomic region likely to 
harbor the causative SNP was reduced by at least 20%. For each of the SNPs in the narrowed 
region, referred to as the 99% credible set, we used HaploReg V2 to annotate their biological 
relevance. HaploReg provides useful annotation information for the SNP of interest as well as 
those within a user-specified LD. The fully operational web version is available at 
http://www.broadinstitute.org/mammals/haploreg/haploreg.php. HaploReg reports any evidence 
for regulatory chromatin marks, DNAse I hypersensitivity sites (DHSI), transcription factor binding 
sites (TFBS), transcription factor binding motifs, or expression quantitative trait loci (eQTL) 
overlapping with each SNP of interest and thus gives mechanistic insights into how non-coding 
SNPs may lead to a given disease condition. Ward and Kellis provide more detailed information 
on HaploReg and its usage.8 
After HaploReg we performed additional annotation manually using annotation resources 
in the public domain (i.e., RegulomeDB, ENCODE, Islet Regulome and FANTOM) to further 
characterize potential regulatory functions of the variants in the credible sets. Use of HaploReg 
together with manual annotation revealed whether a given SNP lies in a location with a histone 
mark suggestive of regulatory activity, a DHSI, TFBS, or if the SNP is in a gene expressed in a 
diabetes-relevant tissue, e.g., the liver or pancreas. In the case of histone marks we also 
evaluated whether the histone mark corresponds to an enhancer or promoter. Finally, we 
catalogued other traits with significant associations reported within the credible set from the 
NHGRI GWAS Catalog. Below we provide detailed information on the potential biological 
relevance of SNPs in each of the 14 FG and 9 FI loci that we annotated; the index SNP in EA 
indicated in parentheses.  
 
1. FOXA2 (rs6048205) 
a. Credible set interval in hg18: chr20:22505099-22508971 
b. Credible set interval in hg19: chr20:22557099-22560971 
c. The region contains the 5’ end of TCONS_00028636 (lincRNA) 
i. Displays especially high expression in liver cell lines 
ii. Is accompanied by moderate to high transcription levels (RNA-seq) only in HepG2 
cell lines 
iii. The EST BG655894 indicates expression in pancreatic Islets 
d. There are five broad and weak H3K4Me1 peaks in the region 
i. Especially prominent in Embryonic stem cells 
e. There are 51 TFBSs in the region, all but 2 are expressed in liver cell lines 
f. The lead SNP is 20bp telomeric (p arm) to a DHSI (19/125) which is found in pancreatic 
islet cell lines 
g. The lead SNP sits inside 10 TFBSs 
i. They are all found in liver cell lines 
ii. Includes FOXA1 and FOXA2  
h. The RNA-seq information from the TFBSs in the region as well as the expression profile 
of the lincRNA indicate that the locus plays a role in the liver. The lead SNPs position in 
several binding sites may lead to a disruption in the binding of TFBSs. 
 
2. GCK (rs4607517) 
 This credible set contained a single SNP; annotation overlap for the SNP can be found in 
Supplemental Table 5. 
 
3. CRY2 (rs11605924) 
a. Credible set interval in hg18: chr11:45820718-45835568 
b. Credible set interval in hg19: chr11:45864142-45878992 
c. Contains 5’ end of CRY2 
d. There is one NHGRI SNP 
i. rs11605924 – fasting glucose traits 
e. There are 7 moderate to weak HK4Me1 peaks in the region 
f. There are 3 weak and 1 strong H3K4Me3 peaks in the region 
g. There are 2 weak and 2 strong H3K27Ac peaks in the region 
h. The lead SNP is 1kbp upstream of a weak H3K4Me1 peak 
i. DHSI (27) found in liver cell lines 
ii. 9 TFBSs 
i. 5.6kbp upstream of weak H3K4Me1 and H3K27Ac peaks 
i. DHSI (57) found in muscle and pancreatic islets 
ii. 3TFBSs 
j. 1kbp downstream of a weak H3K4Me1 peak 
i. DHSI (3) and (32) 
k. 3.8kbp downstream of dual H3K4me1, H3K4Me3, and H3K27Ac peaks 
i. DHSI (111) and (125) 
ii. 101 TFBSs 
l. 6.5kbp telomeric (p arm) to the SNP is a strong H3K4Me3 peak 
m. 8kbp telomeric to the SNP are weak H3K4Me1, H3K27Ac, H3M4Me3 peaks 
i. DHSI (125) 
ii. 49 TFBSs 
n. The lead SNP lies in the promoter region of CRY2, which explains its proximity to several 
H3K4Me1 peaks. Because CRY2 impacts metabolism, a polymorphism in the gene’s 
promoters may alter the function. 
 
4. KL (rs576674) 
a. Credible set interval in hg18: chr13:32209005-32701555 
b. Credible set interval in hg19: chr13:33311005-33803555 
c. Four genes in the region 
i. 3’ end of PDS5B 
ii. KL 
iii. STARD13 
iv. TCONS_00021632 (lincRNA) 
d. Four NHGRI GWAS SNPs 
i. rs2555603 – BMI 
ii. (not related) rs2555603 – aneurysm 
iii. (not related) rs642899 –behavioral disinhibition 
iv. (not related) rs990324 – total ventricular volume 
e. There are 29 H3K4Me1 peaks throughout the region 
f. There are two H3K4Me3 peaks (weak) 
g. 15 H3K27Ac peaks throughout the region 
h. The lead SNP lies within a FOXA2 binding site found in liver cell lines 
i. This is clustered near three other binding sites, all found in liver cell lines 
 i. 10.5kbp telomeric (q arm) to a moderate H3K4Me1 peak and weak H3K4Me3 and 
H3K27Ac peaks 
i. DHSI (66) found in muscle and pancreatic cells 
ii. 6 TFBSs 
j. 4.6kbp upstream of a DHSI (26) in pancreatic islets 
i. 12 TFBSs 
k. The lead SNP is in an intergenic region, and may serve as a bidirectional, distant regulator 
to both TCONS_00021632 and KL. The SNP may impact the binding of FOXA2 to its 
TFBS, and exert its effects primarily in the liver. 
 
5. ADCY5 (rs11708067) 
This credible set contained a single SNP; annotation overlap for the SNP can be found in 
Supplemental Table 5. 
 
6. GCKR (rs780094) 
This credible set contained a single SNP; annotation overlap for the SNP can be found in 
Supplemental Table 5. 
 
7. PROX1 (rs340874) 
a. Credible set interval in hg18: chr1: 212212012-212230298 
b. Credible set interval in hg19: chr1:214145389-214163675 
c. Contains the 5’UTRs of PROX-AS1 and PROX1 
d. Exonic to the mRNA AK096113, overlaps PROX-AS1. Found in liver cell lines 
e. The 5’UTR of PROX-AS1 overlaps the mRNA AK096113, which comes from human liver 
cells 
f. There are 2 NHGRI SNPs in the region 
i. rs2075423 – Type 2 Diabetes 
ii. rs340874 – Fasting glucose traits 
g. There are 4 H3K4Me1 peaks throughout the region 
h. There is one weak and one strong H3K4Me3 peaks 
i. There are two H3K27Ac peaks 
j. The 5’UTR of PROX1 is overlaps with a level of moderate transcription according to RNA-
seq, especially strong in HepG2 cell lines (2.2kbp telomeric to (p arm) lead SNP) 
i. There are also moderate H3K4Me1 and H3K27Ac peaks and a strong H3K4Me3 
peak 
ii. There is a DHSI (116/125) with 36 TFBSs (31 present in liver cells) 
1. TFBSs include FOXA1 and FOXA2 
k. 12.5kbp downstream, there is a large H3K4Me1 peak, with a DHSI (25/125) found in 
HSMM cells and one TFBS 
l. 8.2kbp downstream, there are strong H3K4Me1 dual peaks and small H3K37Ac peaks. 
There is a DHSI (27/125) and 9 TFBSs 
m. The lead SNP lies within an area of mild H3K4Me1 expression and several different DHSI 
and 41 TFBSs (31 expressed in liver cells) 
i. The SNP is within two TFBSs: EZH2 and CTBP2 
n. The histone modifications are consistent with the location of the SNP within the promoter 
region of PROX1 and PROX1-AS1. This area may play an important role in the liver, as 
indicated by the tissue specificity of TFBSs, RNA-seq, and human mRNA. 
  
8. DPYSL5 (rs1371614) 
a. Credible set interval in hg18: chr2: 26957635-27251700 
b. Credible set interval in hg19: chr2:27104131-27398196 
c. Contains 12 different genes 
i. DPYSL5 
ii. MAPRE3 
iii. TMEM214 
iv. OST4 
v. KHK 
vi. EMILIN1 
vii. AGBL5 
viii. CGREF1 
ix. ABHD1 
x. PREB 
xi. C2orf53 
xii. TCF23 
d. The 3’UTR of DYPSL5 contains high transcription levels, according to RNA-seq 
e. Two NHGRI SNPs 
i. rs1371614 – Fasting glucose traits 
ii. (not related) rs7588926 – Response to cytadine analogues 
f. There are 23 H3K4Me1 peaks throughout the region 
g. There are 12 H3K4Me3 peaks throughout the region 
h. There are 14 H3K27Ac peaks throughout the region 
i. The lead SNP lies with a DHSI (3) and 2 TFBSs, FOXA1 and FOXA2, both found in liver 
cell lines 
j. 4kbp downstream of a small H3K4Me1 peak  
i. DHSI (26) found in liver, muscle, and pancreatic cell lines 
ii. 23 TFBSs, all found in liver cell lines 
k. 13kbp upstream of an area of weak H3K4Me1 modification 
i. DHSI (113) and 13 TFBSs 
l. This is a larger transethnic region, with explains the large amount of genes with associated 
histone modifications. The SNP may impact the binding of FOXA1 and FOXA2, specifically 
in liver cells, which would affect liver metabolism. 
 
9. IGF2BP2 (rs7651090)  
a. Credible set interval in hg18: chr3: 186750043-187067565 
b. Credible set interval in hg19: chr3:185267349-185584871 
c. Five genes in the region 
i. LIPH 
ii. SENP2 
iii. IGF2BP2 
1. Human mRNA BC021290 indicates expression in pancreas 
iv. C3Orf65 
v. TCONS_00006340 (lincRNA) 
d. Five NHGRI GWAS SNPs 
i. (not related) rs720390 – height 
ii. rs1374910 – Type 2 Diabetes 
iii. rs6769511 – Type 2 Diabetes 
 iv. rs1470579 – Type 2 Diabetes 
v. rs4402960 – Type 2 Diabetes 
e. There are 24 H3K4Me1 peaks throughout the region 
f. There are 3 H3K4Me3 peaks throughout the region 
g. There are 15 H3K27Ac peaks throughout the region 
h. The lead SNP is intronic to IGF2BP2 
i. 1.3kbp downstream of large H3K4Me1 and H3K27Ac peaks 
i. DHSI (93) and 28 TFBSs 
j. 12kbp downstream of a DHSI (87)  
i. 29 TFBSs 
k. 4.7kbp upstream of a moderate H3K4Me1 peak 
i. DHSI (12) 
l. 13kbp upstream of an area of moderate H3K4Me1  
i. DHSI (60) found in muscle and pancreatic cells 
ii. 5 TFBSs 
m. The large Type 2 Diabetes SNP cloud indicates the importance of the region in that 
disease. The lead SNP is intronic to IGF2BP2, and 27 kbp from the nearest exon. Its role 
may be with the nearby putative promoter, located 1.3 kbp away. Further validation could 
show if this promoter is associated with IGF2BP2, or the downstream lincRNA 
TCONS_00006340. 
 
10. CDKN2B (rs10811661) 
a. Credible set interval in hg18: chr9: 22118180-22124094 
b. Credible set interval in hg19: chr9:22128180-22134094 
c. No genes within the region 
d. 4 NHGRI GWAS SNPs 
i. rs7020996 – Type 2 diabetes 
ii. rs2383208 – Type 2 Diabetes 
iii. rs10965250 – Type 2 Diabetes 
iv. rs10811661 – Type 2 Diabetes 
e. There are three moderate, broad H3M4Me1 peak, especially prominent in blood vessel 
cells 
i. 4kbp, 4.6kbp, and 5.4kbp telomeric (p arm) to the lead SNP 
f. 4.5kbp telomeric to the SNP, there is a DHSI (36/125) which is in HSMM and pancreatic 
islet cells. There are three TFBSs nearby, including FOXA2 
g. The entire region is intergenic and contains a large Type 2 Diabetes SNP cloud. This 
indicates the importance of the enhancer region, which overlaps a DHSI site with tissue 
specificity in diabetes-relevant tissues.  
 
11. ADRA2A (rs10885122) 
a. Credible set interval in hg18: chr10: 112960941-113029657 
b. Credible set interval in hg19: chr10:112970951-113039667 
c. No genes in region 
d. Only histone modification is a very small H3K4Me1 peak between 113,005,278-
113,007,774 only in HSMM cells 
e. There is a DHSI (8/125) in HSMM and PanIsletD.  
f. There are 9 TFBSs in the region, and 7 are present in liver cell lines 
g. **When using lift over, the lead SNP lies just outside the credible region** (113042093) 
 h. This trans-ethnic region contains little biological information, being both intergenic and 
having little regulatory information. However, the information that is available shows tissue 
specificity to diabetes-relevant tissues, and may impact a genomic element not currently 
reported.  
 
12. TCF7L2 (rs7903146) 
a. Credible set interval in hg18: chr10: 114742493-114778805 
b. Credible set interval in hg19: chr10:114752503-114788815 
c. The entire region is intronic to TCF7L2 
i. Human mRNA FJ010174 indicates expression in pancreatic, hepatic, renal, muscle 
and adipose cells 
d. There are five NHGRI GWAS SNPs 
i. rs12243326 – 2 hour glucose challenge 
ii. (not related) rs7904519 – Breast cancer 
iii. rs7903146 – Type 2 diabetes 
iv. rs4506565 – fasting glucose traits/Type 2 Diabetes 
v. rs7901695 – Type 2 diabetes 
e. There are 5 H3K4Me1 peaks (two strong, three weak) 
i. The weak peaks are located 2.3kbp, 3.8kbp, and 5kbp downstream from the lead 
SNP 
f. 8.8kbp downstream, there is a DHSI (8/125) preset in liver cell lines with 21 TFBSs, all 
present in liver cell lines 
i. This coincides with a very strong peak of conservation 
g. The large Type 2 Diabetes SNP cloud, along with the tissue specificity information from 
the human mRNA, confirms the region’s importance in diabetes. The SNP may play a role 
in the promoter regions and impact the transcription of TCF7L2, which is important in 
maintaining blood glucose levels. (http://www.ncbi.nlm.nih.gov/gene/6934) 
 
 
13. FADS1 (rs174550) 
a. Credible set interval in hg18: chr11: 61307932-61366326 
b. Credible set interval in hg19: chr11:61551356-61609750 
c. There are five genes in the region 
i. MYRF 
ii. FEN1 
1. EST CA868349 indicating expression in pancreas 
iii. TMEM258 
iv. FADS1 
v. FADS2 
1. EST BP237803 indicating expression in liver 
d. There are 20 NHGRI GWAS SNPs 
i. rs174541 – metabolite levels 
ii. rs4246215 – platelet counts, phospholipid levels 
iii. rs174538 – blood metabolite levels 
iv. rs102275 – blood cholesterol/metabolite levels, metabolic syndrome 
v. (not related) rs174537 – colorectal cancer 
vi. rs174556 – blood metabolite levels 
vii. rs174555 – blood fatty acid levels 
 viii. rs174550 – fasting glucose related traits 
ix. rs174548 – blood metabolite levels 
x. rs174547 – metabolic traits 
xi. rs174546 – metabolic syndrome, cholesterol 
xii. rs174578 – blood metabolite levels 
xiii. rs2727271 – blood metabolite levels 
xiv. rs2727270 – fatty acid levels 
xv. (not related) rs174583 – response to statins 
xvi. (not related) rs174577 – P wave duration 
xvii. rs174574 – phospholipid levels 
xviii. rs1535 – metabolic syndromw 
xix. (not related) rs174570 – glycated hemoglobin levels 
xx. rs968567 – blood metabolite levels 
e. Seven H3K27Ac peaks 
i. Two are associated with H3K4Me1 peaks  
f. There are three H3KeMe3 peaks, all associated with H3K27Ac peaks 
g. There are eleven H3K4Me1 peaks, seven are associated with H3K27Ac peaks 
h. The lead SNP is intronic to FADS1 
i. The lead SNP is inside of a H3K4Me1 peak 
j. 12kbp upstream are strong H3K4Me3 and H3K27Ac peaks 
i. associated with several DHSI (55,117,124,125,14). The 14/125 DHSI is in both 
hepatocytes and pancreatic cells. There are over 150 associated TFBSs 
ii. On either side of this region are H3K4Me1 peaks 
k. 3.9kbp upstream of H3K4Me1 and K3K17Ac peaks 
i. DHSI (12) found in pancreatic islet cells 
ii. 42 TFBSs 
l. 11kbp telomeric (q arm) to H3K4Me3 and H3K27Ac peaks 
i. DHSI (125) and (116) 
ii. 87 TFBSs 
m. This region contains an expansive SNP cloud, which strengthens the case for the 
importance of the region in Type 2 Diabetes. Furthermore, several of the genes in the 
region are associated with metabolism and cholesterol, including FADS1 and FADS2. The 
location of the lead SNP within a promoter region may impact the transcription of these 
elements. 
 
 
14. DGKB-TMEM195 (rs2191349)  
a. Credible set interval in hg18: chr7: 14888532-15032137 
b. Credible set interval in hg19: chr7:14922007-15065612 
c. Contains the 5’ end of DGKB 
d. Contains 3 NHGRI SNPs 
i. rs10244051 – metabolic traits 
ii. rs2191349 – fasting glucose related traits 
iii. rs6947830 – metabolic syndrome 
e. There are three small H3K4Me1 peaks 
i. 8.7kbp telomeric (p arm) there is a DHSI (104) with HSMM, HepG2, and PanIslets cell 
lines. There are 16 TFBSs   
f. This transethnic region is mostly intergenic, with few biological elements. However, the 
presence of a SNP cloud indicates the importance of this region to Type 2 diabetes. The 
 SNP cloud is clustered around a small H3K4Me1 peak, which may be involved in distant 
regulation. 
 
 
15. ARL15 (rs4865796) 
a. Credible set interval in hg18: chr5: 53059217-53557802 
b. Credible set interval in hg19: chr5:53023460-53522045 
c. There are two genes in the region 
i. TCONS_l2_00022897 (lincRNA) 
ii. 3’ end of ARL15 
1. EST AV660016 indicating expression in liver 
d. There are 5 NHGRI SNPs in the region 
i. rs4311394 – adiponectin levels 
ii. rs6450176 – adiponectin levels/cholesterol 
iii. (not related) rs273218 – migraine 
iv. rs702634 – Type 2 diabetes 
v. (not related) rs255758 – rheumatoid arthritis 
e. There are 14 H3K4Me1 peaks 
i. There is one small peak located 1.5kbp downstream of the SNP 
ii. 7kbp upstream there is a small peak, associated with a DHSI (42) present 
in HepG2 Cells and 7 TFBSs 
f. There are 3 H3K17Ac peaks, each corresponding to a H3K4Me1 peak 
g. There are numerous DHSI and TFBS throughout the region, as well as low-levels of 
transcription according to RNA-seq 
h. The lead SNP is located near a promoter region intronic to ARL15. While this may regulate 
the gene, which is shown to have tissue specificity to the liver and play a role in glucose 
levels via adiponectin (PMID: 20011104), it may also impact regulation of the downstream 
lncRNA TCONS_l2_00022897. 
 
 
16. PPP1R3B (rs4841132) 
This credible set contained a single SNP (rs1461729); annotation overlap for the SNP can be 
found in Supplemental Table 5. 
 
17. COBLL1-GRB14 (rs7607980) 
a. Credible set interval in hg18: chr2: 165214970-165266498 
b. Credible set interval in hg19: chr2:165506724-165558252 
c. There are two genes in the region 
i. 3’ end of COBLL1 
1. EST CB270545 indicates expression in adipose tissue 
ii. TCONS_00004484 (lncRNA) 
1. Increased expression in liver and adrenal tissue. 
d. Five NHGRI GWAS SNPs 
i. rs10195252: Triglycerides 
ii. rs13389219: Waist hip ratio 
iii. (not related) rs6717858: sexual dimorphism is anthropometric traits 
 iv. rs12328675: cholesterol 
v. rs7607980: fasting insulin traits 
e. Between 165,536,302-165,558,065 (coinciding with COBLL1), there is moderate to high 
transcription according to RNA-seq 
i. This is especially prominent in HepG2 cells 
f. 1.3kbp downstream, there is a DHSI (5/125) present in HepG2 cells, with 25 TFBSs (17 
present in liver cells) 
g. 3.1kbp upstream, there is a DHSI (32) present in HSMM, PANC-1, and HepG2, associated 
with 7 TFBSs (all in liver cells) 
h. There is a moderate H3K4Me1 peak and small H3K27Ac peak in the region 
i. This trans-ethnic region shows several instances of tissue specificity in liver tissue, 
including information from TFBSs, DHSI, and lncRNA expression profiles. The lead SNP 
is exonic to COBLL1, which plays a role in cholesterol levels (PubMed: 17903299). This 
variant may impact the function of this gene. 
 
 
18. IRS1 (rs2943634)  
a. Credible set interval in hg18: chr2: 226735108-226872748 
b. Credible set interval in hg19: chr2:227026864-227164504 
c. There are three genes in the region 
i. TCONS_l2_00015614 (lncRNA) – especially prominent in thyroid 
ii. TCONS_00003502 (lncRNA) 
iii. TCONS_00004599 (lncRNA) 
d. There are seven NHGRI GWAS SNPs 
i. rs2972146 – triglycerides/HDL cholesterol 
ii. rs2943641 – Type 2 Diabetes 
iii. rs2943650 – adiposity 
iv. rs1515110 – adiponectin levels 
v. rs2972146 – triglycerides/HDL cholesterol 
vi. (not related) rs2943636 - sexual dimorphism is anthropometric traits 
vii. rs2943634 – fasting insulin traits 
e. There are five H3K4Me1 peaks 
i. 12.7kbp centromeric (q arm) – especially prominent in HSMM cell lines 
ii. 10kbp telomeric – especially prominent in HSMM cell lines 
f. There are three H3K27Ac peaks, each coinciding with a H3K4Me1 peak 
i. 12.7kbp centromeric (q arm) – especially prominent in HSMM cell lines 
ii. 10kbp telomeric – especially prominent in HSMM cell lines 
g. 12.7kbp centromeric is a DHSI (21)  with 9 TFBS (all in liver cells) 
h. 10kbp telomeric are two DHSIs with 27 TFBSs 
i. This region contains only non-coding SNPs, highlighting their importance in metabolic 
disorders. The SNP cloud resides in an intergenic area of the region, with relatively few 
genomic features. However, the genomic features that are present display tissue 
specificity to Type 2 Diabetes relevant tissues. Further validation could uncover if this area 
serves as a distant regulator to another genomic area involved in Type 2 Diabetes. 
 
19. GCKR (rs780094) 
This credible set contained a single SNP; annotation overlap for the SNP can be found in 
Supplemental Table 5. 
 
 20. ANKRD55-MAP3K1 (rs459193) 
a. Credible set interval in hg18: chr5: 55595454-56092481 
b. Credible set interval in hg19: chr5:55559697-56056724 
c. There are five genes in the region 
i. TCONS_00009667 (lncRNA) 
ii. TCONS_00010339 (lncRNA) – especially prominent in kidney and adrenal 
iii. TCONS_00009669 (lncRNA) – especially prominent in kidney and adrenal 
iv. TCONS_00010343 (lncRNA) – especially prominent in kidney and adrenal 
1. 3’ end located less than 1kbp from lead SNP 
v. TCONS_00010346 (lncRNA) 
d. There are 11 NHGRI GWAS SNPs 
i. rs9686661 – triglycerides 
ii. (not related) rs11743303 - sexual dimorphism is anthropometric traits 
iii. rs6867983 – waist circumference/triglycerides 
iv. rs30360 – fasting insulin/insulin resistance 
v. (not related) rs456867 – urate levels 
vi. (not related) rs1020388 – Celiac’s disease 
vii. (not related) rs889312 – breast cancer 
viii. (not related) rs16886181 – breast cancer 
ix. (not related) rs16886165 – breast cancer 
x. (not related) rs16886034 – breast cancer 
xi. (not related) rs16886113 – breast cancer 
e. There are approximately 28 H3K4Me1 peaks 
f. The region has 1 H3K4Me3 peak 
g. There are seven H3K27Ac peaks, each coinciding with a H3K4Me1 peak 
h. 6kbp centromeric (q arm) is an area of high conservation and transcription according to 
RNA-seq. While there is no gene, histone mod, or TFBS corresponding to this region, 
there are 41 ESTs 
i. 9kb centromeric there is a H3K4Me1 peak. There is a DHSI (41) with 10 TFBSs 
i. The DHSI is present in HSMMtube and PanIsletD cell lines 
j. 3.1kbp centromeric is a DHSI (6) present in HepG2 cells. There are 6 TFBSs, all present 
in liver cell lines 
k. 5.5 kbp telomeric is a H3K4Me1 peak. There is a DHSI (48) with 11 TFBSs.  
i. The DHSI is present in HSMM and HepG2 cell lines 
l. 15 kbp telomeric is a broad H3K4Me1 peak. This encompasses several DHSI and TFBSs 
m. This region contains numerous lncRNA and regulatory elements, further emphasizing their 
importance. The tissue specificity of these elements in Type 2 Diabetes tissues, such as 
liver and muscle tissue, indicates that these features may be playing a role in the metabolic 
disorder. Further validation could be done to identify the specific targets of these areas. 
 
21. FAM13A (rs3822072) 
a. Credible set interval in hg18: chr4: 89840095-90083469 
b. Credible set interval in hg19: chr4:89621072-89864446 
c. Contains two genes 
i. 3’ end of HERC3 
ii. FAM13A 
1. The entire region of the gene shows transcription levels particularly prominent in 
HepG2 cell lines 
d. There are two NHGRI GWAS SNPs 
i. (not related) rs2609255 – lung disease 
 ii. rs3822072 – HDL cholesterol 
e. The region has 15 H3K4Me1 peaks 
f. There are 2 H3K4Me3 peaks (each coinciding with an Me3 peak) 
g. There are 6 H3K27Ac peaks (each coinciding with an Me3 peak) 
h. The lead SNP is intronic to FAM13A, is within a DHSI (4) and a TFBS (GATA3) 
i. 3.3kbp upstream there are peaks for each form of histone modification. 
i. DHSI (119) and approximately 70 TFBSs 
j. 9kbp downstream is a DHSI (17) with 11 TFBSs, all present in liver cells 
k. The lead SNP in this region resides in the promoter region of the short isoform FAM13A, 
and may impact its rate of transcription. The tissue-specificity of the RNA-seq and TFBSs 
to the liver indicates where this effect may occur.  
 
22. UHRF1BP1 (rs4646949) 
a. Credible set interval in hg18: chr6: 34872900-35090036 
b. Credible set interval in hg19: chr6:34764922-34982058 
c. Contains three genes 
i. 3’ end of UHRF1BP1 
ii. TAF11 
iii. 5’ end of ANKS1A 
d. There are 6 NHGRI GWAS SNPs 
i. (not related) rs3734266 – lupus 
ii. (not related) rs2140418 – alcoholism 
iii. (not related) rs1535001 – lupus 
iv. (not related) rs847845 – lung cancer 
v. (not related) rs12205331 – CAD 
vi. rs4646949 – fasting insulin traits 
e. There are 18 H3K4Me1 peaks 
f. There is one H3K4Me3 peak 
g. There are eight H3K27Ac peaks 
h. The lead SNP is inside an area of high transcription according to RNA-seq and in between  
the short isoform of UHRF1BP1 and TAF11, but intronic to the long isoform of UHRF1BP1 
i. 1kbp telomeric (p arm) is a small H3K4Me1 peak 
i. DHSI (1) with 6TFBSs 
j. 12kbp telomeric are strong H3K4Me1 and H3K27Ac peaks 
i. DHSI (33) In HSMM and PanIsletD cell lines 
ii. 33 TFBSs, with 32 in blood tissue 
k. 10kbp centromeric are strong H3K4Me3 and H3K27Ac peaks, and a moderate H3K3Me1 
peak 
i. There are several DHSIs (35,20,125,110) 
ii. Over 100 TFBSs 
l. The lead SNP resides near the 3’ end of two different genes, which explains its high rate 
of transcription. However, the small H3K4Me1 peak where the lead SNP resides may be 
a distant regulator of the downstream target ANKS1A, which has been previously 
identified in an obesity and Type 2 diabetes study (PMCID: PMC3364960).  
 
23. PPARG (rs17036328) 
a. Credible set interval in hg18: chr3: 12311507-12371955 
b. Credible set interval in hg19: chr3:12336507-12396955 
c. The entire region is intronic to PPARG 
d. There are 2 NHGRI GWAS SNPs 
 i. (not related) rs11128603 - PAI-1 levels 
ii. rs1801282 – Fasting glucose and Type 2 Diabetes 
e. The region has only one strong H3K4Me1 peak, and six other weak peaks 
f. There are 3 weak H3K27Ac peaks, each coinciding with a Me1 peak 
g. The lead SNP is 3kbp downstream of the strong H3K4Me1 peak and a weak Me3 peak 
i. There is a DHSI (67) found in muscle and pancreatic cell lines 
ii. There are 17 TFBSs 
h. 1.7kbp Upstream of a DHSI (51) found in muscle and pancreatic cell lines. There are 27 
TFBSs 
i. 4.4 kbp upstream of a DHSI (40) found in HepG2 and HSMM cell lines 
i. There are 24 TFBSs  
j. While the region is intronic to the long isoform of PPARG, the lead SNP is 2.7kbp upstream 
of the 5’ end of the short isoform. The nearby promotor signals, DHSI, and TFBSs may be 
involved in the regulation of this isoform. Genetic variations impacting PPARG may 
increase the risk for Type 2 Diabetes (PubMed: 15797964, PubMed 15592662, PubMed: 
12882888).  
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Figure S1. Schematic study diagram.36 fasting glucose (FG) loci, 16 fasting insulin (FI) loci, 
and 2 loci associated with both FG and FI previously identified in European ancestry (EA) samples 
were fine-mapped by combining association statistics from EA and African ancestry (AA) samples 
using Meta-ANalysis of TRans-ethnic Association studies (MANTRA) software. Substantially 
reduced trans-ethnic credible sets were further examined for evidence of regulatory annotation or 
enrichment of regulatory marks. Known loci from EA samples were also analysed for 
transferability to AA samples, for evidence of independent signals in AA populations, and for 
evidence of selection. Novel FG- and FI-associated loci were identified in fixed effects GWAS 
meta-analysis in AA samples alone and in trans-ethnic analyses combining EA and AA samples. 
Two novel loci associated with FI and 24 loci known from EA samples were examined for 
association with other cardiometabolic traits.  
 
Figure S2. Venn diagram of trans-ethnic analysis and transferability results. Venn diagram 
showing loci exhibiting transferability between EA and AA in brown, loci at which 99% credible 
set was reduced by at least 20% shown in blue, and overlapping loci in the central area.  
 
Figure S3. Trans-ethnic fine-mapping of 22 loci (13 FG, 8 FI, and 1 both FG and FI) with 
greater than 20% reduction in the 99% credible set. Trans-ethnic analysis of glycemic 
quantitative loci provides narrowed intervals spanned by the 99% credible set. 500 kb regional 
association plots centered at the index SNP identified from EA samples at each locus. The X-axis 
denotes genomic position and the Y-axis denotes the log (Bayes factor), recombination rate and 
varLD information. The red diamond data point represents the index SNP within the region 
previously reported from the EA sample. The color of each data point indicates its LD value (r2) 
with the index SNP based on HapMap 2 (YRI for AA results and CEU for EA results): white, r2 not 
available; blue, r2=0.0-0.2; brown, r2=0.2-0.5; orange, r2=0.5-0.8; red, r2=0.8-1.0. The blue line 
represents the recombination rate. The green line shows  the varLD score at each SNP and is  
highlighted with dark brown if the varLD score is  > 95th percentile of the genome-wide varLD 
score, comparing LD information between YRI and CEU HapMap2 samples52. The interval 
spanned by the 99% credible set is highlighted in pink. For each locus, three figures were provided. 
Panel A. Association results using EA samples. Panel B. Association results using AA 
samples. Panel C. Association results using both EA and AA samples. 
Figure S4. Overlay of regional association plots with regulatory annotation at 22 loci (13 
FG, 8 FI, and 1 both FG and FI) with greater than 20% reduction in the 99% credible set. 
Top panel: 500 Kb genomic span showing the top SNP in EA (MAGIC) with a diamond, the top 
SNP in AA (AAGILE) with a triangle, the EA-only 99% credible set bounded by the blue and pink 
boxes, and the narrowed trans-ethnic 99% credible set indicated by the pink boxes. SNPs are 
colored according to score assigned in RegulomeDB with lower score corresponding to stronger 
level of evidence supporting regulatory function. Lower panel (where shown): A zoomed in 
region of the locus, showing either a 100 Kb or a 50 Kb genomic span. Again, the top SNP in EA 
(MAGIC) is represented by a diamond, SNPs are colored according to score assigned in 
RegulomeDB with lower score corresponding to stronger level of evidence supporting regulatory 
function, and the blue box indicates the span of the EA-only 99% credible set while the pink box 
indicates the narrowed trans-ethnic 99% credible set. Data from the Islet Regulome Browser for 
the genomic interval are shown below the regional association plots. 
Figure S5. Concordance of effect size and Comparison of EA trait-raising allele Frequency 
in EA and AA. We show the concordance of effect (Figures S5A and S5B) and comparison of 
 frequency (Figures S5C and S5D) for each EA trait-raising allele between EA and AA samples. 
The blue rectangles represent the SNPs meeting SNP transferability criteria from EA to AA, i.e. 
association P < 0.05 in AA and sharing the trait-raising allele in EA and AA. Grey circles represent 
SNPs without evidence of SNP transferability. In Figures S5A and S5B, X-axis is the effect size 
in EA and Y-axis is the effect size in AA for the EA trait-raising allele. There is evidence of excess 
concordance of effect between EA and AA. Specifically, of 36 EA FG index SNPs, 28 SNPs share 
the same direction in AA (binomial test P of 5.96 x 10-4), (Figure S5A); of 18 EA FI index SNPs, 
14 SNPs share the same direction in AA (binomial test P of 1.544E-2), (Figure S5B). Also, for 
both traits, SNPs that meet the transferability criteria tended to have larger effect size of similar 
magnitudes in both the EA and AA samples than those not meeting criteria. In Figures S5C and 
S5D, X-axis is the frequency in EA and Y-axis is the frequency in AA for the EA trait-raising allele. 
There is wide variation in the frequency of the EA trait-raising allele between EA and AA; the 
majority of SNPs with locus transferability from EA to AA exhibit higher frequency of the EA trait-
raising allele in AA than in EA.  
Figure S6. Genome-wide association plots and quantile-quantile (QQ) plots for FG and FI. 
Figures S6A and S6C display the Miami plots of association, which mirror the results of AA (on 
the top) and EA (on the bottom). The X-axis is the chromosome and position and the Y-axis is the 
–log-scale of association P. Figures S6B and S6D are the QQ plots for FG and FI, respectively. 
Both associations of FG and FI are minimally inflated with lambda of 1.018 and 1.028, respectively. 
Figures S6E and S6F are the genome-wide association plots of trans-ethnic meta-analysis 
results for FG and FI, respectively. The X-axis is the chromosome and position and the Y-axis is 
the –log-scale of association P.   
Figure S7. Conditional analysis at PELO/rs6450057. The product of the sign of the beta-
coefficient for FI level and –log(P-value) for each SNP residing ±250kb of the top SNP, rs6450057, 
at the locus in EA samples (MAGIC) and in AA samples (AAGILE) plotted on the X- and Y-axis, 
respectively. Figures S7A and 7C show the comparison for unconditional association results with 
HapMap 2 CEU and YRI LD information, respectively. Figures S7B and S7D show the 
comparison for conditional association results with HapMap 2 CEU and YRI LD information, 
respectively. There is a clear pattern in the discordant directions of effect between EA and AA. 
However, after conditional analysis on the top SNP, this discordant pattern disappears, implying 
that the top SNP rs6450057 drives the original association signal. 
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